|
Active substance |
Midostaurin (PKC412) |
|
Holder |
Novartis Pharma |
|
Status |
Closed |
|
Indication |
Newly diagnosed FLT3 mutated acute myeloid leukemia patients eligible for standard induction and consolidation chemotherapy. |
|
Public documents |
|
|
Last update |
09/10/2018 |
Rydapt®
Last updated on 02/10/2024